

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2

In re application of :
 Shouji KAMIYA et al. : **Mail Stop: PCT**
 Serial No. 10/521,175 : Attorney Docket No. 2005_0042A
 Filed January 14, 2005 :

NOVEL INDOLINE COMPOUND AND
 MEDICINAL USE THEREOF
**[Corresponding to PCT/JP03/09012
 Filed July 16, 2003]**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Shouji KAMIYA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
April 22, 2005

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 22, 2005

ATTY DOCKET NO.
2005_0042ASERIAL NO.
10/521,175APPLICANT
Shouji KAMIYA et al.FILING DATE
January 14, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,063,806	5/2000	Kamiya et al.			
	AB	6,200,988	3/2001	Kamiya et al.			
	AC	6,169,107	1/2001	Kitano et al.			
	AD	6,248,772	6/2001	Kitano et al.			
	AE	5,990,150	11/1999	Matsui et al.			
	AF	6,127,403	10/2000	Matsui et al.			
	AG	6,204,392	3/2001	Matsui et al.			
	AH	6,414,012	7/2002	Matsui et al.			
	AI	6,489,475	12/2002	Matsui et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	4-66568	3/1992	JP			Abstract
	AK	0 512 570	11/1992	EP			
	AL	0 622 356	11/1994	EP			Corresponds to Refs AC & AD
	AM	0 708 091	4/1996	EP			Corresponds to Refs AC & AD
	AN	96/09287	3/1996	WO			Corresponds to Refs AF - AI

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	V. DeVries et al., "Potential Antiatherosclerotic Agents . 5. ¹ An Acyl-CoA:Cholesterol O-Acyltransferase Inhibitor with Hypocholesterolemic Activity", J. Med. Chem., Vol. 29, 1986, pp. 1131-1133.
	AP	Fredrick J. Brown et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1,6-Disubstituted Indoles and Indazoles", J. Med. Chem., Vol. 33 (6), 1990, pp. 1771-1781.
	AQ	Victor G. Matassa et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles", J. Med. Chem., Vol. 33(6), 1990, pp. 1781-1790.

EXAMINER

DATE CONSIDERED

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 22, 2005

ATTY DOCKET NO.
2005_0042ASERIAL NO.
10/521,175APPLICANT
Shouji KAMIYA et al.FILING DATE
January 14, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	5,994,040	11/1999	Morishima et al.			
	BB	5,091,419	2/1992	Ito et al.			
	BC	5,166,429	11/1992	Ito et al.			
	BD	5,384,425	1/1995	Ito et al.			
	BE	5,227,492	7/1993	Ito et al.			
	BF	4,803,218	2/1989	Stanley et al.			
	BG	4,956,372	9/1990	Kojima et al.			
	BH	5,767,129	6/1998	Yuen			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BI	8-208602	8/1996	JP			Corresponds to Refs AC & AD
	BJ	0 793 140	9/1997	EP			Corresponds to Ref BA
	BK	2-117651	5/1990	JP			Corresponds to Refs BB - BE

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BL	K. Yee et al., "Novel Series of Selective Leukotriene Antagonists: Exploration and Timization of the Acidic Region in 1,6-Disubstituted Indoles and Indazoles ¹ ", J. Med. Chem., Vol. 33(9) 1990, pp. 2437-2451.
	BM	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: April 22, 2005

ATTY DOCKET NO.
2005_0042ASERIAL NO.
10/521,175APPLICANT
Shouji KAMIYA et al.FILING DATE
January 14, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	5,153,226	10/1992	Chucholowski et			
	CB	5,254,590	10/1993	Malen et al.			
	CC	5,254,565	10/1993	Meguro et al.			
	CD	5,256,782	10/1993	Meguro et al.			
	CE	5,143,919	9/1992	Meguro et al.			
	CF	5,219,859	6/1993	Festal et al.			
	CG	5,258,405	11/1993	Ito et al.			
	CH	5,420,348	5/1995	Ito et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	CI	3-148247	6/1991	JP			Corresponds to Ref CA
	CJ	4-327564	11/1992	JP			Corresponds to Ref CB
	CK	3-7259	1/1991	JP			Corresponds to Ref CC
	CL	5-32666	2/1993	JP			Corresponds to Refs CD & CE
	CM	5-97802	4/1993	JP			Corresponds to Ref CF
	CN	5-140102	6/1993	JP			Corresponds to Ref AK
	CD	8-92210	4/1996	JP			Corresponds to Refs AE - AI
	CP	4-234839	9/1992	JP			Corresponds to Refs CG & CH

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	CQ	
--	----	--

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.